NASDAQ:CSBR
Champions Oncology, Inc.
Champions Oncology, Inc.'s revenue grew 4.4% in fiscal 2026 to $59.4M while operating margin fell to −1.9%. Free cash flow was −$5.0M, −8.5% of revenue, and the diluted share count fell 3.0%.Summary generated from Champions Oncology, Inc.'s SEC filings. Latest annual report filed Jul 27, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$59.4M
Revenue growth+4.4%
Revenue, 5-yr CAGR+7.7%
Gross margin48.0%
Operating margin−1.9%
Net margin−2.0%
ROICn/a
Return on equity−30.5%
Debt / equityn/a
Free cash flow−$5.0M
FCF margin−8.5%
Share count change−3.0%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 49 | 54 | 50 | 57 | 59 |
| Operating income | 1 | −5 | −7 | 5 | −1 |
| Net income | 1 | −5 | −7 | 5 | −1 |
| Free cash flow | 4 | 1 | −7 | 7 | −5 |
Recent filings
- 10-QQuarterly report for the period ended Jul 31, 2026
Sep 11, 2026 - 8-KResults of operations and financial condition
Sep 10, 2026 - DEF 14AProxy statement
Aug 28, 2026 - 10-KAnnual report for the fiscal year ended Apr 30, 2026
Jul 27, 2026 - 8-KResults of operations and financial condition
Jul 27, 2026 - 8-KDirector or officer change
Mar 30, 2026 - 10-QQuarterly report for the period ended Jan 31, 2026
Mar 12, 2026 - 8-KResults of operations and financial condition
Mar 12, 2026